Trade Summary

5 days ago, Cannon Gillian, serving as Dir at Xenon Pharmaceuticals Inc. (XENE), sold 1,190 shares at $53.14 per share, for a total transaction value of $63,236.60. Following this transaction, Cannon Gillian now holds 1,455 shares of XENE.

This sale represents a 44.99% decrease in Cannon Gillian's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, June 5, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 9, 2026 (accepted Jun 8, 9:19 PM ET), 4 days after the trade was made.

Xenon Pharmaceuticals Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.